Search

Displaying results 5091 - 5100 of 5925 in total
  1. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    Pegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D). … FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction.

  2. Drug

    ONO-2952

    go.drugbank.com/drugs/DB14802
    Investigational

    investigation in clinical trial NCT01887002 (Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

  3. Drug

    Myrcludex B

    go.drugbank.com/drugs/DB14853
    Investigational

    Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D)

  4. Drug

    GW-468816

    go.drugbank.com/drugs/DB15099
    Experimental

    GW-468816 is under investigation in clinical trial NCT00218465 (Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking).

    Categories: Receptors, N-Methyl-D-Aspartate, antagonists & inhibitors
  5. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [A261120] Pozelimab is a human, monoclonal immunoglobulin G4<sup>P</sup> antibody against the terminal complement protein C5.

  6. Drug

    Olorofim

    go.drugbank.com/drugs/DB15245
    Investigational

    Olorofim is under investigation in clinical trial NCT03340597 (Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects).

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Substrates
  7. Drug

    Risdiplam

    go.drugbank.com/drugs/DB15305
    ApprovedInvestigational

    Risdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA). It increases systemic SMN protein concentrations by improving the efficiency of SMN2 gene transcription. This mechanism o...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  8. Drug

    Danicopan

    go.drugbank.com/drugs/DB15401
    ApprovedInvestigational

    [A263501,L50411] Danicopan is a small molecule complement factor D inhibitor that selectively blocks the alternative pathway, thereby working to address extravascular hemolysis when used in conjunction

    Categories: P-glycoprotein inhibitors, Complement Factor D Inhibitor
  9. Drug

    Yersinia pestis 195/p antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB15461
    Investigational

    Yersinia pestis 195/p antigen (formaldehyde inactivated) is under investigation in clinical trial NCT02596308 (Immunogenicity and Safety of Subunit Plague Vaccine).

    Synonyms: Yersinia pestis 195/p antigen (formaldehyde inactivated)
  10. Drug

    Mexazolam

    go.drugbank.com/drugs/DB15489
    Investigational

    Mexazolam (CS-386) is a benzodiazepine indicated for the treatment of anxiety with or without psychoneurotic conditions. Mexazolam's structure is similar to that of other benzodiazepines such as oxazolam and cloxazolam. The use of benzod...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates